secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277564
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02, 3.01, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA terminates ATM facility, faces NYSE delisting notice; CFO and CMO fired
----------------------------------------------------------------------------

- Terminated at-the-market equity sales agreement with ThinkEquity; had raised ~$1.67M through Nov 15, 2023.
- NYSE American orally advised MAIA of non-compliance with stockholders' equity rule ($2.7M vs $4M minimum).
- CFO Joseph McGuire and CMO Dr. Mihail Obrocea terminated effective Nov 10; severance $330k and $418k respectively.
- Jeffrey Himmelreich appointed Head of Finance and principal accounting officer; base salary $210k.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/0001193125-23-277564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000119312523277564/d882839d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer